key: cord-0876473-xlewch4s authors: Bime, Christian; Casanova, Nancy G.; Nikolich-Zugich, Janko; Knox, Kenneth S.; Camp, Sara M.; Garcia, Joe G.N. title: Strategies to DAMPen COVID-19-Mediated Lung and Systemic Inflammation and Vascular Injury date: 2020-12-20 journal: Transl Res DOI: 10.1016/j.trsl.2020.12.008 sha: 81ff05e674c01828bb96852644c69594fbddd8ae doc_id: 876473 cord_uid: xlewch4s Approximately 15%-20% of patients infected with SARS-CoV-2 coronavirus (COVID-19) progress beyond mild and self-limited disease to require supplemental oxygen for severe pneumonia; 5% of COVID-19-infected patients further develop acute respiratory distress syndrome (ARDS) and multi-organ failure. Despite mortality rates surpassing 40%, key insights into COVID-19-induced ARDS pathology have not been fully elucidated and multiple unmet needs remain. This review focuses on the unmet need for effective therapies that target unchecked innate immunity-driven inflammation which drives unchecked vascular permeability, multi-organ dysfunction and ARDS mortality. Additional unmet needs including the lack of insights into factors predicting pathogenic hyperinflammatory viral host responses, limited approaches to address the vast disease heterogeneity in ARDS, and the absence of clinically-useful ARDS biomarkers. We review unmet needs persisting in COVID-19-induced ARDS in the context of the potential role for damage-associated molecular pattern proteins in lung and systemic hyperinflammatory host responses to SARS-CoV-2 infection that ultimately drive multiorgan dysfunction and ARDS mortality. Insights into promising stratification-enhancing, biomarker-based strategies in COVID-19 and non-COVID ARDS may enable the design of successful clinical trials of promising therapies. Within the ten months following notification by the World Health Organization's (WHO) China Country Office of a pneumonia of unknown cause detected in the city of Wuhan (Hubei province, China) (January 2020), the COVID-19 pandemic, now known to be caused by Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), has fundamentally altered global health and economies and changed our country, community and families [1] . To date (November 2020), the pandemic has resulted in more than 55 million infected individuals worldwide and ~1.3 million deaths [2] . Whereas the majority (80%) of patients with confirmed SARS-CoV-2 infection exhibit mildly symptomatic, self-limited coronavirus disease (COVID- 19) , approximately 15% of infected subjects progress to severe pneumonia requiring supplemental oxygen and 5% further progress to develop acute respiratory distress syndrome (ARDS), and/or multi organ failure (MOF) [3] (Figure 1 ) which drives mortality rates that surpass 40%. Over 80% of COVID-19-infected patients resolve a self-limited disease in Stage I. Approximately 15% of infected subjects, however, progress to severe pneumonia requiring supplemental oxygen (Stage II) with 5% further developing acute respiratory distress syndrome (ARDS), and/or multi-organ failure (Stage III). Stages II and III are characterized by dysregulated lung and systemic inflammation which are essential contributors to COVID-19 disease severity. Adapted from Siddiqi et al [4] . The unprecedented nature of the SARS-CoV-2/COVID-19 pandemic has highlighted multiple unmet medical needs including the glaring absence of effective FDA-approved targeted pharmacotherapies [5] . This has created urgency within basic science, translational, and clinical research communities, particularly as immunityderived protection against the novel coronaviruses such as SARS (severe acute respiratory syndrome, [2002] [2003] [2004] , and MERS (Middle East respiratory syndrome, 2012-2015) proved to be inefficient and unpredictable [6, 7] . The availability of effective SARS-CoV-2 vaccines and anti-SARS-CoV-2 drugs are imminent and of obvious utility, however, neither therapeutic strategy addresses the pathobiology of COVID-19-ARDS i.e. the unremitting activation of innate immunity inflammatory pathways with unchecked lung and systemic inflammation. The activation of evolutionarily-conserved inflammatory cascades by SARS-CoV-2, as well as significant amplification of these pathways by exposure to excessive levels of ventilator-induced mechanical stress [8] , results in massive increases in circulating levels of inflammatory cytokines producing vascular leak, edema of multiple critical organ (lung, kidneys, heart, brain, liver, gastrointestinal tract), and dysregulated activation of the coagulation cascade, ultimately leading to multi-organ dysfunction and death [9] [10] [11] . Studies of past coronavirus outbreaks, involving SARS-CoV-1 [12, 13] and MERS-CoV [14] , have increased our understanding of the inflammation-induced pathobiology in SARS-CoV-2 revealing such commonalities as the cytokine-release syndrome. Other immune responses to SARS-CoV-2, however, remain distinctive [15, 16] including the unique expanded tropism of SARS-CoV-2 for vascular endothelial cells, likely relevant to the hypercoagulability observed in severe COVID-19 [16, 17] . In addition, SARS-CoV-2 infectivity peaks before the onset of symptoms, a stark contrast to SARS-CoV-1 [3, 18] , reflecting current understanding of longer SARS-CoV-2 incubation periods and higher rates of transmission compared to other coronaviruses [5] . Potential mechanisms for the significant differences in the host immune response to SARS-CoV-2 infection include viral escape from innate sensing, hyper-inflammatory responsiveness referable to inflammatory myeloid subpopulations, and lymphopenia marked by T cell and Natural Killer cell dysfunction among other alterations such as hypercoagulability [4, 19, 20] . Clearly, additional studies are needed to more fully define immune responses to specific coronavirus infections, including SARS-CoV-2, that dictate disease severity. In this report, we summarize potential mechanisms of COVID-19 pathobiology regarding increases in vascular leakage, hypercoagulation initiation, and the promotion of lung and systemic inflammation. In addition, we examine the underpinnings of the multiple unmet needs in COVID-19 ARDS which includes the absence of effective therapies that target unchecked activation of lung and systemic inflammatory cascades by damage-associated molecular pattern proteins which ultimately drives ARDS multiorgan dysfunction and mortality. Acknowledging the difficulty in identifying specific ARDS sub-phenotypes, due to heterogeneity in host responses to SARS-CoV-2 infection, we also highlight the unmet need for biomarkers predictive of a pathologic hyperinflammatory viral host response versus a physiologic host response [21] [22] [23] . Insights into promising stratification-enhancing, biomarker-based strategies in COVID-19 and non-COVID ARDS may enable the design of successful clinical trials of promising therapies. An important first step to addressing the multiple and critical unmet needs in severe COVID-19 infection is to understand the pathogen-activated innate immunity pathways designed to contain the infection but which produce unremitting inflammation in a subset of infected patients. Both SARS-CoV and SARS-CoV-2 consist of four main structural glycoproteins; the spike (S) protein responsible for viral binding and entry into host cell, and membrane (M), envelope (E), and nucleocapsid (N) proteins which play an important role in viral particle assembly and release [24] . Human angiotensin converting enzyme 2 (ACE2) has been identified as an entry receptor for SARS-CoV [25] and SARS-CoV-2 [24] . Membrane fusion after host cell binding is facilitated by Sprotein cleavage by host cell proteases, specifically, the transmembrane serine protease 2 [26] . The dependence on ACE2 for viral entry contributes to the tropism for nasal ciliated epithelium and alveolar type II pneumocytes [5] . Increased infectivity and novel clinical features of SARs-CoV-2 have been associated with the tropism for other ACE2-expressing cells such as endothelial cells which is conferred by acquisition of a furin cleavage site on the S-protein [24] . Key homeostatic functions of the vascular endothelium include presenting a nonthrombotic surface to circulating components and serving as a semi-permeable barrier to the extravasation of blood proteins, fluid and infiltrating leukocytes [27] . The hallmark of COVID-19-and non-COVID-19 ARDS is the loss of endothelial cell barrier integrity resulting in vascular leakage and increased tissue edema in multiple vital organs, most prominently the lung (Figure 2) . The pathobiological mechanisms that potentially cause increased vascular permeability in severe SARS-Co-V-2 infection may include a direct viral infection of endothelial cells [17] , activation of the kallikrein-bradykinin pathway, and the activation of permeability-inducing signaling pathways by adherent platelets, activated neutrophils [28] and circulating cytokines and vasoactive molecules [20] . The increased mechanical stress produced by mechanical ventilation as well as impaired endothelial cell ACE2 activity may also contribute to increases in vascular permeability [26] . Multiple studies, including our own, have underscored the critical role of the endothelial cell cytoskeleton in vascular barrier regulation and repair that is central to the pathobiology of ARDS and ventilator-induced lung injury (VILI) [27, 29] . ii) vascular responses to excessive mechanical stress in VILI, and iii) regulation of leukocyte transmigration to the alveolar space. In addition, several cytoskeletal target genes harbor variants which contribute to the genetic basis for observed ARDS health disparities in Americans of African descent [30] [31] [32] [33] [34] . Despite the identification of unchecked vascular permeability as a critical feature of progression to ARDS mortality, to date, there are no FDA-approved therapies that directly address the severe vascular leak that is critical to COVID-and non-COVID ARDS pathobiology and outcomes. Critical sequence of coronaviral-and mechanical stressmediated activation of evolutionarily-conserved inflammatory cascades resulting in dysregulated cytokine release, hypercoagulation, and leukocyte-endothelial cell interactions and diapedesis. In combination with excessive levels of reactive oxygen species (ROS) generated in target endothelial cells, these combined effects result in vascular injury and triggering of the cytoskeletal contractile apparatus to increase permeability leading to organ edema, multiorgan failure and COVID-19 ARDS mortality. After the initial phase of SARS-CoV-2 infection, 20% of patients develop severe or critical illness based on the severity of lung inflammation, hypoxemia, respiratory failure including ARDS, septic shock and/or multi-organ dysfunction [19, 20] (Figure 1 ). The progressive lung damage is a combination of a profound pro-inflammatory cytokine storm as well as coagulation abnormalities with a high incidence of thrombotic events observed in patients with severe COVID-19-ARDS [35] (Figure 2 ). As noted above, although the nasal ciliated epithelium and alveolar type II pneumocytes are the initial point of invasion by SARS-CoV-2, activated endothelial cells play a critical role in the pathogenesis of COVID-19 associated ARDS and multi-organ dysfunction [20] . Unique features of SARS-CoV-2 include the ability of the virus to directly affect endothelial cells, causing endothelialitis [17] and dysregulated coagulation pathways [15, 16] . Granulocyte-containing microthrombi are a common feature of severe COVID-19 disease [35] , a phenomenon described as immuno-thrombosis. This highly coagulative and inflammatory state is the result of a complex interplay between activated platelets, primed neutrophils and activated vascular endothelial cells [36] . The formation of platelet neutrophil complexes at the surface of endothelial cells, leads to recruitment of highly cytotoxic neutrophils and inflammation-activated platelets that translocate through the pulmonary microvasculature into the alveolar and pulmonary interstitial spaces contributing to endothelial cell injury (Figure 2 ) [37] . Sequestration of platelet/neutrophil complexes in the pulmonary vasculature produces micro-thrombi and micro-emboli in the alveolo-capillary circulation. This highly inflammatory and pro-coagulant state also leads to hyperactivation of the coagulation cascade and a relative exhaustion of the fibrinolytic system [36, 38] . The regulatory mechanisms of these hyperinflammatory and hypercoagulable responses in COVID-19 are still under investigation, however, it merits stressing that COVID-19-related coagulation disorders (arterial thrombosis, pulmonary embolism etc.) are closely related to innate immune activation and inflammation, with a strong influence of Toll-like receptors [39] . Currently, the role of anticoagulant therapies in COVID disease is speculative and under investigation although patients with elevated D Dimer or confirmed clots appear to benefit from systemic anticoagulation. Despite the critical importance for risk of thrombotic complications and the contribution to COVID-19 morbidity and mortality, there are no FDA-approved therapies that directly address endothelial cell dysregulation associated with increased coagulation/thrombosis in COVID and non-COVID ARDS. Amplification. SARS-CoV-2 is a cytopathic virus which induces cellular death and local release of various damage-associated molecular pattern proteins (DAMPs) and pathogenassociated molecular pattern proteins (PAMPs) [40] . Pattern-recognition receptors such as Toll-like family of receptors (TLRs) recognize PAMPs in the extracellular space, triggering expression and activation of pro-inflammatory transcription factors such as NF-κB [41, 42] . These interactions also trigger the activation of interferon-regulatory factors that mediate antiviral responses [41, 42] . Given their master regulatory role in A key feature of patients who progress from Stage I COVID-19 disease to increasingly severe Stage II and Stage III disease is blood biomarker evidence of the In COVID-19 ARDS, the utility of plasma biomarkers as important diagnostic or prognostic biomarkers and as targets for therapeutics remains under investigation. Discussion of relevant or promising ARDS biomarkers is germane to addressing the previously emphasized major unmet need for successful ARDS therapies. The prominent role of DAMP-mediated hyperinflammation in COVID-19 ARDS initially led to rapid repurposing of anti-inflammatory drugs for COVID-19 ARDS that were previously shown to be effective for cancer and autoimmune disorders indications. Unfortunately, multiple clinical trials with anti-inflammatory drugs have failed leading to speculation that therapeutic targeting of the "cytokine storm" that is emblematic of non-COVID ARDS may be of limited utility in COVID-19-ARDS [56] . The primary basis for this line of reasoning has evolved from two observations which center on the interleukin-6 (IL-6) pathway, a well-recognized inflammatory pathway in ARDS pathobiology [57, 58] . First, median circulating IL-6 levels in five COVID-19 cohorts were observed to be lower when serum [62] and other therapeutic modalities [63] [64] [65] are constantly curated and cataloged. Although a hyper-inflammatory response to SARS-CoV-2 is a major cause for morbidity and mortality in COVID-19, there are currently no biomarkers that are predictive of pathogenic inflammatory responses, reliably predict did ease severity/mortality, or that are able to identify targetable immune pathways. General biomarkers of inflammation influencing the DAMP-mediated inflammatory cascade activation is minimal [68, 69] . We have previously utilized genomic-intensive approaches [70] [71] [72] and cellular and preclinical studies [10, 73, 74] of bacterial pneumonia and excessive mechanical stress/ventilator-induced lung injury (VILI) to identify eNAMPT as a novel DAMP and essential participant in ARDS/VILI pathobiology. Circulating eNAMPT functions as a master regulator of evolutionarily-conserved inflammatory cascades via ligation of Tolllike receptor 4 (TLR4) [73] eliciting profound NFkB-driven inflammatory processes involved in ARDS/VILI pathobiology, including the loss of lung vascular barrier integrity [10, 73, 74] (Figure 3) . We and others have demonstrated key NAMPT SNPs present at minor allelic frequencies >5% in both non-Hispanic whites and in Blacks, confer increased risk of developing sepsis/trauma-induced ARDS/VILI and confer increased ARDS severity and mortality (reduced ventilator-free days, increased ARDS mortality) [72, [75] [76] [77] . Importantly, leveraging preclinical murine, rat and porcine studies of ARDS/VILI, we demonstrated that eNAMPT is a highly druggable target [10, 73] with a humanized eNAMPT-neutralizing mAb proven to be efficacious in preclinical ARDS/ VILI models [74, 78] (Figure 3 ). In response to a variety of injurious ARDS-relevant stimuli, including trauma, hypoxia, mechanical stress (generated by mechanical ventilation) and SARS-CoV2 infection, the NAMPT gene is activated, primarily in epithelial cells, leukocytes and vascular endothelial cells, to generate and secrete eNAMPT into the blood [10, 73] . Circulating eNAMPT functions as a damage-associated molecular pattern protein or DAMP via ligation of pathogen-recognition receptor, TLR4, eliciting NFkB-mediated gene expression and activation of systemic inflammatory cascades [73] . The elaborated cytokines i.e. the "cytokine storm", produce systemic inflammation with increases in vascular permeability, organ edema and multi-organ failure, the main contributor to ARDS mortality. In addition to ARDS-associated NAMPT SNPs and genotypes, eNAMPT is tightly linked to human ARDS by eNAMPT levels that are elevated in in plasma and BAL in ARDS subjects and serve as a biomarker for human ARDS severity [55, 72, 79, 80] . Americans at increased risk of death from ARDS [30, 32, 84, 85] that has been dramatically highlighted in the current COVID-19 pandemic [86] , the recruitment of ARDS cohorts with substantial diversity is mandated. Such diverse cohorts would improve our current understanding of ARDS biomarkers, allow for discovery of novel biomarkers, improve our ability to stratify patients for enrollment into clinical trials, and allow the prioritization of clinical interventions. Studies conducted with diverse "at risk" cohorts for ARDS mortality should focus on identification of high-risk ARDS subjects potentially incorporating an anti-inflammatory platform which combines the availability of predictive biomarkers, point of care ARDS genotype testing, and a highly efficacious biologic or small molecule therapy. These strategies may provide the best opportunity to deliver personalized medicine in the current COVID-19 pandemic landscape and to directly address the unmet need for strategies to improve ARDS outcomes. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Comparative Global Epidemiological Investigation of SARS-CoV-2 and SARS-CoV Diseases Using Meta-MUMS Tool Through Incidence, Mortality, and Recovery Rates Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression Host Immune Responses to SARS Coronavirus in Humans Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection Activation of NLRP3 inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung inflammation and injury Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury Ventilator-Induced Lung Injury: Classic and Novel Concepts The clinical pathology of severe acute respiratory syndrome (SARS): a report from China Pathology and pathogenesis of severe acute respiratory syndrome Pathogenesis of Middle East respiratory syndrome coronavirus Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases Endothelial cell infection and endotheliitis in COVID-19 SARS-CoV-2 detection, viral load and infectivity over the course of an infection Pathogenesis of COVID-19-induced ARDS: implications for an ageing population COVID-19: the vasculature unleashed The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cytoskeletal regulation of pulmonary vascular permeability Evolving functions of endothelial cells in inflammation Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury. American journal of respiratory cell and molecular biology Racial Differences in Mortality from Severe Acute Respiratory Failure in the United States Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma Racial and ethnic disparities in mortality from acute lung injury Novel polymorphisms in the myosin light chain kinase gene confer risk for acute lung injury Race and gender differences in acute respiratory distress syndrome deaths in the United States: An analysis of multiple-cause mortality data (1979-1996)*. Critical care medicine Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy Preventing the development of severe COVID-19 by modifying immunothrombosis PAMPs and DAMPs as triggers for DIC Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation Coagulation Disorders in COVID-19: Role of Toll-like Receptors Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome The Pyrin Inflammasome in Health and Disease Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19 High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes Neural-respiratory inflammasome axis in traumatic brain injury The trinity of COVID-19: immunity, inflammation and intervention Dissecting antibody-mediated protection against SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Effect of Intravenous Interferon beta-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Serum Ferritin is an independent risk factor for Acute Respiratory Distress Syndrome in COVID-19 Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. The Lancet Respiratory medicine Development of a biomarker mortality risk model in acute respiratory distress syndrome Is a "Cytokine Storm" Relevant to COVID-19? IL6 gene-wide haplotype is associated with susceptibility to acute lung injury Pleiotropic effects of interleukin-6 in a "two-hit" murine model of acute respiratory distress syndrome Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 The pro-and antiinflammatory properties of the cytokine interleukin-6 Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Society RAP. COVID-19 Therapeutics Tracker COVID-19 Treatment and Vaccine Tracker BIO COVID-19 Therapeutic Development Tracker An inflammatory cytokine signature predicts COVID-19 severity and survival Laboratory biomarkers associated with COVID-19 severity and management Reducing the burden of acute respiratory distress syndrome: the case for early intervention and the potential role of the emergency department Anti-TNFalpha therapy in inflammatory lung diseases Orthologous gene-expression profiling in multi-species models: search for candidate genes Microarray analysis of regional cellular responses to local mechanical stress in acute lung injury Pre-Bcell colony-enhancing factor as a potential novel biomarker in acute lung injury Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NFkappaB Signaling and Inflammatory Lung Injury Endothelial eNAMPT Amplifies Preclinical Acute Lung Injury: Efficacy of an eNAMPT-Neutralising mAb Pre-B-cell colonyenhancing factor gene polymorphisms and risk of acute respiratory distress syndrome Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study The NAMPT promoter is regulated by mechanical stress, signal transducer and activator of transcription 5, and acute respiratory distress syndrome-associated genetic variants An eNAMPT-neutralizing mAb reduces rat and porcine lung injury severity in preclinical ARDS/VILI Clinical role of serum pre-B cell colonyenhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis Mechanical stress induces pre-B-cell colony-enhancing factor/NAMPT expression via epigenetic regulation by miR-374a and miR-568 in human lung endothelium Endotoxinand mechanical stress-induced epigenetic changes in the regulation of the nicotinamide phosphoribosyltransferase promoter Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling. Transcriptional Regulation by SOX and HIF-2alpha. American journal of respiratory cell and molecular biology Recent trends in acute lung injury mortality Healthcare disparities in patients with acute respiratory distress syndrome. Toward equity The Structural and Social Determinants of the Racial/Ethnic Disparities in the What's Our Role? We would like to acknowledge the contributions of the following: Dr.